ProCE Banner Activity

CE / CME

An Expert’s Perspective: Where We Are and What Lies Ahead in Treating IgAN

Clinical Thought

As the treatment landscape continues to evolve with positive results from phase III clinical trials and FDA-approval of novel therapies, learn where nephrologists and other healthcare professionals currently stand and what challenges lie ahead in managing patients with immunoglobulin A nephropathy.

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: January 25, 2024

Expiration: January 24, 2025

Share

Faculty

Pietro Canetta

Pietro Canetta, MD, MS

Associate Professor of Medicine
Division of Nephrology
Columbia University Irving Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC, in partnership with the American Kidney Fund.

ProCE Banner

Supporters

Supported by educational grants from Calliditas Therapeutics AB and Travere Therapeutics.

Calliditas Therapeutics AB

Travere Therapeutics

Partners

American Kidney Fund

ProCE Banner

Target Audience

This program is intended for physicians—including residents and fellows—nurse practitioners, and physician associates practicing in nephrology and primary care who manage patients with IgAN.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in evaluating the latest data from Kidney Week 2023 and integrating the most clinically important data to clinical practice for appropriate management of patients with IgAN.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify key data presented at Kidney Week 2023 on IgAN

  • Translate key data on IgAN presented at Kidney Week 2023 to patient care

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Pietro Canetta, MD, MS

Associate Professor of Medicine
Division of Nephrology
Columbia University Irving Medical Center
New York, New York

Pietro Canetta, MD, MS: consultant/advisor/speaker: Chinook; data and safety monitoring board: Otsuka.

The planners and content peer reviewers from Clinical Care Options, LLC and the American Kidney Fund do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from January 25, 2024, through January 24, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC and the American Kidney Fund. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Physician Associate Continuing Medical Education
Joint AccreditationClinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until January 24, 2025. PAs should only claim credit commensurate with the extent of their participation.

 

American Board of Internal Medicine Maintenance of Certification  

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).